<DOC>
	<DOCNO>NCT01493518</DOCNO>
	<brief_summary>The purpose study study safety , tolerability immunogenicity AMG 557 follow multiple subcutaneous dose administration adult moderate severe psoriasis .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics , Pharmacodynamics , Clinical Effects AMG 557 Adults With Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Subjects must sign Institutional Review Board ( IRB ) approve informed consent form ( ICF ) study specific procedure . Diagnosis moderate severe plaque PsO least 6 month prior screen define : A minimum PASI score ≥ 10 obtained screening ; Psoriasis involve ≥ 10 % Body Surface Area ( BSA ) screening . Received least 1 previous phototherapy systemic PsO therapy ( within 30 day study drug administration ) , candidate receive phototherapy systemic PsO therapy opinion PI . Stable treatment without topical systemic steroid , topical systemic retinoids , vitamin D analogue ( Dovenex ) , Psoralen Ultraviolet A ( PUVA ) therapy , Ultraviolet A ( UVA ) therapy Ultraviolet B ( UVB ) therapy , methotrexate , cyclosporine least 60 day prior IP administration . Stable treatment PsO involve scalp , axilla , groin topical corticosteroid moderate strength allow . Agrees wear clothe protects sun exposure duration study . Agrees use sunscreen ( SPF least 30 ) sunexposed skin duration study . Male female subject 18 55 year age , inclusive time screen . Body mass index ( BMI ) 18 35 kg/m2 , inclusive , screening , unless consider PI Amgen Medical Monitor appropriate value context measure safety parameter . Able willing complete entire study ( include skin biopsy ) accord study schedule . Additional criterion per protocol . Diagnosis guttate , pustular , non plaque form PsO . Evidence skin condition PsO ( eg , eczema ) screening period would interfere evaluation effect IP PsO . Previous receipt approve investigational biologic agent PsO medical condition . Received PUVA therapy , UVA therapy UVB therapy ≤ 30 day prior IP administration . Treatment systemic PsO therapy oral parenteral corticosteroid ≤ 30 day prior IP administration . Use high potency topical steroid , topical vitamin A D analog preparation , anthralin ≤ 30 day prior IP administration ( Note : stable dos &gt; 30 day low moderate strength topical steroid permit scalp , axilla , groin accord package insert ) . Received topical cyclosporin calcineurin inhibitor pimecrolimus ( Elidel ) tacrolimus ( Protopic ) ≤ 30 day prior IP administration . Received IV oral calcineurin inhibitor tacrolimus ( Prograf ) ≤ 30 day prior IP administration . Significant concurrent medical condition time screen prior randomization , include : Uncontrolled hypertension ( define screen systolic blood pressure measurement great 140 mm Hg screen diastolic blood pressure great 90 mm Hg ) confirm 2 separate measurement screen visit ; Unstable angina pectoris ; Congestive heart failure ; Steroid oxygen dependent chronic obstructive pulmonary disease ; Diagnosis multiple sclerosis demyelinate disease ; Open cutaneous ulcer ; Uncontrolled diabetes ( HbA1c &gt; 7 % ) . History myocardial infarction . Subjects two cardiovascular risk factor ( define BMI &gt; 30 , BP systolic &gt; 140 mm Hg , diagnosis diabetes , history cardiovascular event ) . Evidence significant renal insufficiency screen period , define glomerular filtration rate &lt; 50 mL/min use Cockcroft Gault equation : 72 x Serum Creatinine ( mg/dL ) / ( 140 Age ) x Body Weight ( kg ) x [ 0.85 female ] Evidence bacterial , viral , parasitic , systemic fungal infection 30 day prior study drug administration ( eg , common cold , viral syndrome , flu like symptom ) . Evidence recent ( within 6 month randomization ) infection require patient hospitalization intravenous antibiotic . Positive test HIV antibody , hepatitis B surface antigen , hepatitis C antibody . Underlying condition predisposes subject infection ( eg , history splenectomy ; history immunodeficiency ) . Evidence past active tuberculosis chest xray perform screening ( documented evidence chest xray perform within 6 month prior plan dosing ) ; know tuberculosis antecedent ; know exposure ( without adequate treatment ) person active tuberculosis ; positive protein purify derivative ( PPD ) Mantoux skin serum quantiferon test screening ( without document history treatment ) . A positive result define either induration great equal 5 mm 4872 hour administration ( Mantoux ) positive serum quantiferon test result . History malignancy . Evidence liver disease ( eg , serum ALT AST &gt; 1.5 x upper limit normal ) screen period . Donated blood ( include blood product ) experience loss blood ≥ 500 mL within 2 month screen . Additional criterion per protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>SAFETY</keyword>
	<keyword>ADULT</keyword>
	<keyword>PSORIASIS</keyword>
	<keyword>INFLAMMATION</keyword>
</DOC>